ImmVira Group, a Shenzhen biotech, raised $10 million in a Series B to develop its next-gen genetically modified oncolytic viruses for cancer. The financing was entirely funded by Shanghai Healthcare Capital, which is affiliated with Shanghai Pharma. In August , Shanghai Pharma in-licensed ImmVira's MVR-T3011 oncolytic virus program in a $165 million deal. MVR-T3011 is a genetically engineered oncolytic herpes simplex virus-1 candidate that expresses PD-1 antibody and interleukin-12 immune modulators. More details.... Share this with colleagues: // //